Metriport said on August 27, 2026 that it raised $26 million in new funding to give clinicians a usable view of a patient’s history at the point of care. Matrix general partner TJ Parker led the round, with ARTIS and Y Combinator participating. Total funding is now $28.4 million.

The San Francisco company, founded in 2022 by CEO Dima Goncharov and COO Colin Elsinga, builds open-source infrastructure that pulls records from major healthcare data sources, then matches, extracts, standardizes, deduplicates, and enriches them into a unified model. Customers named in the release include Amazon One Medical, Sollis Health, and Color Health. Access is via API, a data warehouse, or apps inside an electronic health record.

Why the round exists

Metriport argues that regulation is forcing more record sharing, but that a pile of documents is not the same as clinical context. Providers still chase faxes and external requests that can take weeks, then make decisions from incomplete histories. Sollis Health chief medical officer Dr. Scott Braunstein described using Metriport to find an old endoscopy report for a patient with abdominal pain, starting treatment without a new CT scan.

Elsinga said the company open-sourced the code because decisions about how patient information is transformed are too important to leave in a black box. Metriport recently achieved HITRUST r2 Certification and says it will use the new capital to scale the platform and expand machine-learning and agentic features. General counsel Matt Davis-Ratner said every prospective customer goes through deep diligence before getting network access.

Decoded Take

Most health AI products assume the record is already clean. Metriport is selling the unglamorous layer that makes that assumption less false: assemble the chart, normalize it, then let summarization sit on top. Open-sourcing the transformation logic is a trust play for hospital IT and a distribution play for builders who do not want another closed interchange. The tension is access control. The same networks that make the product valuable are the ones Metriport has to police. Watch whether the new money shows up as more named health systems and published open-source adoption, or as a thicker agent layer that starts to look like every other clinical copilot.